Want to see ORGO full AI Analyst Report?
ORGO Stock Chart & Stats
$1.74
$0.13(5.44%)
At close: 4:00 PM EDT
$1.74
$0.13(5.44%)
Day’s Range― - ―
52-Week Range$0.93 - $7.08
Previous CloseN/A
Volume86.56K
Average Volume (3M)668.00K
Market Cap
$131.25M
Enterprise Value$472.65M
Total Cash (Recent Filing)$46.10M
Total Debt (Recent Filing)$66.95M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Nov 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding128,674,550
10 Day Avg. Volume828,331
30 Day Avg. Volume667,998
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap3.60
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda-261.28
Forecast
1Y Price Target
$2.00Price Target Upside14.94% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$196.05M
Bulls Say, Bears Say
Bulls Say
Cash GenerationPositive operating and free cash flow provide an important source of internal funding despite reported losses. If sustained, this cash generation can support core operations, reduce dependence on external capital, and give management time to execute its recovery and cost-reduction plans.
Cost RestructuringThe restructuring program creates a measurable path toward a lower fixed-cost base, with workforce reductions and additional quarterly savings already identified. This should improve operating leverage if revenue stabilizes, making a return toward breakeven more achievable over the next several quarters.
Clinical EvidenceA broad clinical evidence base can strengthen physician adoption, payer discussions, and repeat utilization of the wound-care portfolio. Demonstrated outcomes in diabetic foot ulcers and large Medicare populations may support more durable market positioning than product claims alone.
Bears Say
Revenue ContractionThe sharply reduced outlook indicates that the business is undergoing a substantial demand and market reset rather than a minor cyclical slowdown. Such a revenue contraction can impair scale, weaken operating leverage, and make the timing of a sustainable recovery highly dependent on execution.
Margin And Loss PressureSevere margin compression combined with widening operating and net losses reduces the company’s ability to convert sales into durable earnings. Persistently weaker profitability could absorb cash, constrain investment in growth initiatives, and delay the benefits expected from restructuring actions.
Financing SensitivityThe substantial cash reduction increases sensitivity to execution and recovery timing, even though management expects funding for at least 12 months. Reliance on an equity facility provides flexibility but can dilute shareholders and signals that external capital may remain relevant.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings Inc’s price range in the past 12 months?
Organogenesis Holdings Inc lowest stock price was $0.93 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings Inc’s market cap?
Organogenesis Holdings Inc’s market cap is $131.25M.
When is Organogenesis Holdings Inc’s upcoming earnings report date?
Organogenesis Holdings Inc’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Organogenesis Holdings Inc’s earnings last quarter?
Organogenesis Holdings Inc released its earnings results on Aug 06, 2026. The company reported -$0.714 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.364.
Is Organogenesis Holdings Inc overvalued?
According to Wall Street analysts Organogenesis Holdings Inc’s price is currently Undervalued.
Does Organogenesis Holdings Inc pay dividends?
Organogenesis Holdings Inc does not currently pay dividends.
What is Organogenesis Holdings Inc’s EPS estimate?
Organogenesis Holdings Inc’s EPS estimate is -0.18.
How many shares outstanding does Organogenesis Holdings Inc have?
Organogenesis Holdings Inc has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings Inc’s price movement after its last earnings report?
Organogenesis Holdings Inc reported an EPS of -$0.714 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -22.822%.
Which hedge fund is a major shareholder of Organogenesis Holdings Inc?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (14.94% Upside)
$2.00 (14.94% Upside)
Blogger Sentiment
Bullish
ORGO Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 13.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.00%
12-Months-Change
Fundamentals
Return on Equity
-24.23%
Trailing 12-Months
Asset Growth
-11.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Organogenesis Holdings Inc
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$2.00
▲(14.94% Upside)
Technical Analysis
Lifecore Biomedical
―
Sonoma Pharmaceuticals
―
Pacira Pharmaceuticals
―
Evolus
―
Journey Medical Corp
―
Ownership Overview
17.00% Insiders
7.01% Mutual Funds
1.74% Other Institutional Investors
61.95% Public Companies and
Individual Investors